Satoshi Noda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satoshi Noda has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Tomohiro Terada
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
6 shared publications Shin-Ya Morita
Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan
4 shared publicationsTomohiro Terada
Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan
4 shared publicationsDaiki Hira
Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu City, Japan
3 shared publications- Shin-Ya Morita
Department of Pharmacotherapeutics, Shiga University of Medical Science, Otsu, Japan
3 shared publications Yoshito Ikeda
Department of Pharmacotherapeutics Shiga University of Medical Science Otsu Shiga Japan
3 shared publications
Latest Publications
- Open Access
- 22 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 1141-1151
Relationships of Proton Pump Inhibitor‐Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study
Proton pump inhibitors (PPIs) have recently been reported to be linked with nephrotoxicity. PPIs are metabolized mainly or partly by cytochrome P450 2C19 (CYP2C19). However, the relationship between CYP2C19 genetic polymorphism and PPI‐induced nephrotoxicity is unclear. In this study, we aimed to analyze the association between the time of occurrence of renal injury by PPIs, including lansoprazole, esomeprazole, rabeprazole, and vonoprazan, and CYP2C19 metabolizer status classified by CYP2C19 genotypes. Patients prescribed PPIs were reviewed in this retrospective cohort study. The primary outcome was the time to a 30% decrease in estimated glomerular filtration rate (eGFR) from baseline. In patients treated with lansoprazole, the time to a 30% decrease in eGFR for the CYP2C19 poor metabolizer (PM) group was significantly shorter than that for the non‐PM group (hazard ratio for PM vs. non‐PM, 2.43, 95% confidence interval, 1.21 to 4.87, P = 0.012). In contrast, in patients that received esomeprazole, rabeprazole, or vonoprazan, no significant differences were found in the time to a 30% decrease in eGFR between non‐PM and PM groups. The adjusted hazard ratios for the time to a 30% eGFR decrease in patients treated with lansoprazole were significantly higher for CYP2C19 PM, hypertension, and a history of myocardial infarction. In conclusion, this retrospective study showed that CYP2C19 metabolizer status was associated with the time to a 30% eGFR decrease in patients treated with lansoprazole, but not with esomeprazole, rabeprazole, or vonoprazan.
- 22 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 1141-1151
Open AccessRelationships of Proton Pump Inhibitor‐Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study
Proton pump inhibitors (PPIs) have recently been reported to be linked with nephrotoxicity. PPIs are metabolized mainly or partly by cytochrome P450 2C19 (CYP2C19). However, the relationship between CYP2C19 genetic polymorphism and PPI‐induced nephrotoxicity is unclear. In this study, we aimed to analyze the association between the time of occurrence of renal injury by PPIs, including lansoprazole, esomeprazole, rabeprazole, and vonoprazan, and CYP2C19 metabolizer status classified by CYP2C19 genotypes. Patients prescribed PPIs were reviewed in this retrospective cohort study. The primary outcome was the time to a 30% decrease in estimated glomerular filtration rate (eGFR) from baseline. In patients treated with lansoprazole, the time to a 30% decrease in eGFR for the CYP2C19 poor metabolizer (PM) group was significantly shorter than that for the non‐PM group (hazard ratio for PM vs. non‐PM, 2.43, 95% confidence interval, 1.21 to 4.87, P = 0.012). In contrast, in patients that received esomeprazole, rabeprazole, or vonoprazan, no significant differences were found in the time to a 30% decrease in eGFR between non‐PM and PM groups. The adjusted hazard ratios for the time to a 30% eGFR decrease in patients treated with lansoprazole were significantly higher for CYP2C19 PM, hypertension, and a history of myocardial infarction. In conclusion, this retrospective study showed that CYP2C19 metabolizer status was associated with the time to a 30% eGFR decrease in patients treated with lansoprazole, but not with esomeprazole, rabeprazole, or vonoprazan.
- 1 January 2023
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2023, 2P2-D20
電磁モータの軽量化を目的としたトルクの平均およびリップルを考慮する回転子鉄心のトポロジー最適化
Reducing the weight of a human-collaborative robot leads to improved safety and increased payload per body mass, enabling it to be used in a wider variety of industries. This study focuses on the electromagnetic motor as one of the components and aims to reduce the weight while maintaining the required average torque. This paper focuses on the rotor core of the IPMSM and uses topology optimization with NGnet to find the optimum structure. The aim is to suppress the torque ripple, which worsened in the previous study due to the weight reduction. Multi-objective optimization for mass minimization and torque ripple minimization with mean torque as a constraint resulted in a low torque ripple and lightweight structure while maintaining mean torque.
- 1 January 2023
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2023, 2P2-D20
電磁モータの軽量化を目的としたトルクの平均およびリップルを考慮する回転子鉄心のトポロジー最適化
Reducing the weight of a human-collaborative robot leads to improved safety and increased payload per body mass, enabling it to be used in a wider variety of industries. This study focuses on the electromagnetic motor as one of the components and aims to reduce the weight while maintaining the required average torque. This paper focuses on the rotor core of the IPMSM and uses topology optimization with NGnet to find the optimum structure. The aim is to suppress the torque ripple, which worsened in the previous study due to the weight reduction. Multi-objective optimization for mass minimization and torque ripple minimization with mean torque as a constraint resulted in a low torque ripple and lightweight structure while maintaining mean torque.
- Open Access
- 3 September 2022
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 36 (5) , 2465-2472
Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients
Background/Aim: Concurrent chemoradiotherapy with high-dose cisplatin (CDDP-RT) is the standard therapy for advanced head and neck cancer; however, due to CDDP-induced renal impairment, dose reduction or discontinuation is frequently required. Therefore, the identification of risk factors for renal impairment is of importance to improve the efficacy and safety of CDDP-RT. Patients and Methods: We retrospectively investigated risk factors for renal impairment in advanced head and neck cancer patients receiving CDDP-RT. Renal impairment was defined as a >25% decrease from baseline in estimated glomerular filtration rate within 14 days after CDDP administration in the first cycle. Results: Of the 82 patients analyzed in this study, 21 (26%) patients developed renal impairment. Multivariate logistic regression analysis showed that concomitant use of a calcium channel blocker or lower hemoglobin levels significantly contributed to the increased risk of CDDP-induced renal impairment (odds ratio=3.60, 95% confidence interval=1.04-12.40; odds ratio=0.71, 95% confidence interval=0.50-0.99, respectively), while concomitant use of proton pump inhibitors was a factor associated with a decreased risk of CDDP-induced renal impairment (odds ratio=0.20, 95% confidence interval=0.04-0.86). Conclusion: Renal function of patients receiving calcium channel blocker or patients with lower hemoglobin levels should be monitored cautiously when receiving CDDP-RT.
- 3 September 2022
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 36 (5) , 2465-2472
Open AccessAnalysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients
Background/Aim: Concurrent chemoradiotherapy with high-dose cisplatin (CDDP-RT) is the standard therapy for advanced head and neck cancer; however, due to CDDP-induced renal impairment, dose reduction or discontinuation is frequently required. Therefore, the identification of risk factors for renal impairment is of importance to improve the efficacy and safety of CDDP-RT. Patients and Methods: We retrospectively investigated risk factors for renal impairment in advanced head and neck cancer patients receiving CDDP-RT. Renal impairment was defined as a >25% decrease from baseline in estimated glomerular filtration rate within 14 days after CDDP administration in the first cycle. Results: Of the 82 patients analyzed in this study, 21 (26%) patients developed renal impairment. Multivariate logistic regression analysis showed that concomitant use of a calcium channel blocker or lower hemoglobin levels significantly contributed to the increased risk of CDDP-induced renal impairment (odds ratio=3.60, 95% confidence interval=1.04-12.40; odds ratio=0.71, 95% confidence interval=0.50-0.99, respectively), while concomitant use of proton pump inhibitors was a factor associated with a decreased risk of CDDP-induced renal impairment (odds ratio=0.20, 95% confidence interval=0.04-0.86). Conclusion: Renal function of patients receiving calcium channel blocker or patients with lower hemoglobin levels should be monitored cautiously when receiving CDDP-RT.
- 1 July 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (7) , 814-823
Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring
Oral multi-kinase inhibitors have transformed the treatment landscape for various cancer types and provided significant improvements in clinical outcomes. These agents are mainly approved at fixed doses, but the large inter-individual variability in pharmacokinetics and pharmacodynamics (efficacy and safety) has been an unsolved clinical issue. For example, certain patients treated with oral multi-kinase inhibitors at standard doses have severe adverse effects and require dose reduction and discontinuation, yet other patients have a suboptimal response to these drugs. Consequently, optimizing the dosing of oral multi-kinase inhibitors is important to prevent over-dosing or under-dosing. To date, multiple studies on the exposure-efficacy/toxicity relationship of molecular targeted therapy have been attempted for the implementation of therapeutic drug monitoring (TDM) strategies. In this milieu, we recently conducted research on several multi-kinase inhibitors, such as sunitinib, pazopanib, sorafenib, and lenvatinib, with the aim to optimize their treatment efficacy using a pharmacokinetic/pharmacodynamic approach. Among them, sunitinib use is an example of successful TDM implementation. Sunitinib demonstrated a significant correlation between drug exposure and treatment efficacy or toxicities. As a result, TDM services for sunitinib has been covered by the National Health Insurance program in Japan since April 2018. Additionally, other multi-kinase targeted anticancer drugs have promising data regarding the exposure–efficacy/toxicity relationship, suggesting the possibility of personalization of drug dosage. In this review, we provide a comprehensive summary of the clinical evidence for dose individualization of multi-kinase inhibitors and discuss the utility of TDM of multi-kinase inhibitors, especially sunitinib, pazopanib, sorafenib, and lenvatinib.
- 1 July 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (7) , 814-823
Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring
Oral multi-kinase inhibitors have transformed the treatment landscape for various cancer types and provided significant improvements in clinical outcomes. These agents are mainly approved at fixed doses, but the large inter-individual variability in pharmacokinetics and pharmacodynamics (efficacy and safety) has been an unsolved clinical issue. For example, certain patients treated with oral multi-kinase inhibitors at standard doses have severe adverse effects and require dose reduction and discontinuation, yet other patients have a suboptimal response to these drugs. Consequently, optimizing the dosing of oral multi-kinase inhibitors is important to prevent over-dosing or under-dosing. To date, multiple studies on the exposure-efficacy/toxicity relationship of molecular targeted therapy have been attempted for the implementation of therapeutic drug monitoring (TDM) strategies. In this milieu, we recently conducted research on several multi-kinase inhibitors, such as sunitinib, pazopanib, sorafenib, and lenvatinib, with the aim to optimize their treatment efficacy using a pharmacokinetic/pharmacodynamic approach. Among them, sunitinib use is an example of successful TDM implementation. Sunitinib demonstrated a significant correlation between drug exposure and treatment efficacy or toxicities. As a result, TDM services for sunitinib has been covered by the National Health Insurance program in Japan since April 2018. Additionally, other multi-kinase targeted anticancer drugs have promising data regarding the exposure–efficacy/toxicity relationship, suggesting the possibility of personalization of drug dosage. In this review, we provide a comprehensive summary of the clinical evidence for dose individualization of multi-kinase inhibitors and discuss the utility of TDM of multi-kinase inhibitors, especially sunitinib, pazopanib, sorafenib, and lenvatinib.
- 29 April 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (2) , 281-288
Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma
Purpose We aimed to evaluate exposure–toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC). Methods In this retrospective, observational study, 28 HCC patients who had been treated with lenvatinib were enrolled between August 2018 and April 2020. We evaluated the association between the trough lenvatinib concentration and occurrence of grade ≥ 3 toxicities. Additionally, we estimated the association of the trough lenvatinib concentration with responder status (disease control; complete response, partial response, or stable disease), and progression-free survival (PFS). Results The mean trough lenvatinib concentration was significantly higher in the group with grade ≥ 3 toxicity (n = 15) than in the group with grade ≤ 2 toxicity (n = 13). Based on the receiver operating characteristic curve, the threshold values of the trough lenvatinib concentrations for predicting grade ≥ 3 toxicities and responder status were 71.4 ng/mL [area under the curve (AUC) 0.86, 95% confidence interval (CI) 0.71–1.00; p < 0.05] and 36.8 ng/mL (AUC 0.95, 95% CI 0.85–1.00; p < 0.05), respectively. Lenvatinib concentrations of 36.8–71.4 ng/mL resulted in longer PFS than concentrations < 36.8 ng/mL and ≥ 71.4 ng /mL [median 13.3 months (36.8–71.4 ng/mL) vs. 3.5 months (< 36.8 ng/mL) and 7.8 months (≥ 71.4 ng /mL), respectively]. Conclusions Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8–71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC.
- 29 April 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (2) , 281-288
Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma
Purpose We aimed to evaluate exposure–toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC). Methods In this retrospective, observational study, 28 HCC patients who had been treated with lenvatinib were enrolled between August 2018 and April 2020. We evaluated the association between the trough lenvatinib concentration and occurrence of grade ≥ 3 toxicities. Additionally, we estimated the association of the trough lenvatinib concentration with responder status (disease control; complete response, partial response, or stable disease), and progression-free survival (PFS). Results The mean trough lenvatinib concentration was significantly higher in the group with grade ≥ 3 toxicity (n = 15) than in the group with grade ≤ 2 toxicity (n = 13). Based on the receiver operating characteristic curve, the threshold values of the trough lenvatinib concentrations for predicting grade ≥ 3 toxicities and responder status were 71.4 ng/mL [area under the curve (AUC) 0.86, 95% confidence interval (CI) 0.71–1.00; p < 0.05] and 36.8 ng/mL (AUC 0.95, 95% CI 0.85–1.00; p < 0.05), respectively. Lenvatinib concentrations of 36.8–71.4 ng/mL resulted in longer PFS than concentrations < 36.8 ng/mL and ≥ 71.4 ng /mL [median 13.3 months (36.8–71.4 ng/mL) vs. 3.5 months (< 36.8 ng/mL) and 7.8 months (≥ 71.4 ng /mL), respectively]. Conclusions Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8–71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC.
- 25 June 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 86 (1) , 129-139
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study
Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC). Methods This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS). Results The median sorafenib concentration was 2.91 μg/mL (range 0.74–8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54–0.93; p p <0.05), respectively. OS of patients with sorafenib 1.40–3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40–3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]. Conclusions From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40–3.45 μg/mL in patients with HCC.
- 25 June 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 86 (1) , 129-139
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study
Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC). Methods This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS). Results The median sorafenib concentration was 2.91 μg/mL (range 0.74–8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54–0.93; p p <0.05), respectively. OS of patients with sorafenib 1.40–3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40–3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]. Conclusions From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40–3.45 μg/mL in patients with HCC.
- 1 April 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (2) , e306-e313
Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma
- 1 April 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (2) , e306-e313
Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma
- Open Access
- 5 October 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 957
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
Chemotherapy-induced oral mucositis impairs the quality of life. The difference in severity of oral mucositis between different anti-epidermal growth factor receptor (EGFR) antibodies combined with cytotoxic drugs in colorectal cancer is unclear. The aim of this study was to investigate the differences in oral mucositis between panitumumab (Pmab) and cetuximab (Cmab) combined with 5-fluorouracil (5-FU). We conducted a retrospective cohort study. A total of 75 colorectal cancer outpatients treated with an anti-EGFR antibody combined with FOLFOX, FOLFIRI, or 5-FU/leucovorin as the first- to third-line treatment were included. The primary endpoint was the incidence of grade 2–3 oral mucositis. The secondary endpoint was the time to onset of oral mucositis. We also compared the incidence of toxicities of interest, skin toxicity, hypomagnesaemia and neutropenia, and time to treatment failure (TTF) between the two groups. Thirty-two patients treated with Pmab and 43 patients treated with Cmab were evaluated. Patient characteristics were similar between the two groups. The incidence of grade 2–3 oral mucositis was significantly higher with Pmab than with Cmab (31.3% vs 9.3%, P < 0.05). Moreover, the incidence of grade 3 oral mucositis was significantly higher in patients treated with Pmab (18.8% vs 0%, P < 0.01). The mean (SD) cycles to onset of the worst oral mucositis was 3.0 (2.9) in the Pmab group and 2.3 (1.7) in the Cmab group (P = 0.29). Oral mucositis was characterized by glossitis and cheilitis. The incidences of other toxicities were the following (Pmab vs Cmab): grade 2–3 skin toxicity: 68.8% vs 74.4% (P = 0.61), grade 2–3 hypomagnesaemia: 9.3% vs 7.0% (P = 1.00), grade 3–4 neutropenia: 28.1% vs 37.2% (P = 0.46). The median TTF was not significantly different, i.e., 223 days vs 200 days (P = 0.39) for Pmab vs Cmab. Pmab-based chemotherapy resulted in significantly higher grades of oral mucositis compared with Cmab-based chemotherapy. The oral condition should be monitored carefully and early supportive care should be provided for patients treated with Pmab-based chemotherapy.
- 5 October 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 957
Open AccessOral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
Chemotherapy-induced oral mucositis impairs the quality of life. The difference in severity of oral mucositis between different anti-epidermal growth factor receptor (EGFR) antibodies combined with cytotoxic drugs in colorectal cancer is unclear. The aim of this study was to investigate the differences in oral mucositis between panitumumab (Pmab) and cetuximab (Cmab) combined with 5-fluorouracil (5-FU). We conducted a retrospective cohort study. A total of 75 colorectal cancer outpatients treated with an anti-EGFR antibody combined with FOLFOX, FOLFIRI, or 5-FU/leucovorin as the first- to third-line treatment were included. The primary endpoint was the incidence of grade 2–3 oral mucositis. The secondary endpoint was the time to onset of oral mucositis. We also compared the incidence of toxicities of interest, skin toxicity, hypomagnesaemia and neutropenia, and time to treatment failure (TTF) between the two groups. Thirty-two patients treated with Pmab and 43 patients treated with Cmab were evaluated. Patient characteristics were similar between the two groups. The incidence of grade 2–3 oral mucositis was significantly higher with Pmab than with Cmab (31.3% vs 9.3%, P < 0.05). Moreover, the incidence of grade 3 oral mucositis was significantly higher in patients treated with Pmab (18.8% vs 0%, P < 0.01). The mean (SD) cycles to onset of the worst oral mucositis was 3.0 (2.9) in the Pmab group and 2.3 (1.7) in the Cmab group (P = 0.29). Oral mucositis was characterized by glossitis and cheilitis. The incidences of other toxicities were the following (Pmab vs Cmab): grade 2–3 skin toxicity: 68.8% vs 74.4% (P = 0.61), grade 2–3 hypomagnesaemia: 9.3% vs 7.0% (P = 1.00), grade 3–4 neutropenia: 28.1% vs 37.2% (P = 0.46). The median TTF was not significantly different, i.e., 223 days vs 200 days (P = 0.39) for Pmab vs Cmab. Pmab-based chemotherapy resulted in significantly higher grades of oral mucositis compared with Cmab-based chemotherapy. The oral condition should be monitored carefully and early supportive care should be provided for patients treated with Pmab-based chemotherapy.
- 10 June 2017
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 43 (6) , 297-305
A Case Report of Elevated PT-INR Associated with Concurrent Use of Sunitinib and Warfarin:
Due to its interaction with many anticancer drugs, warfarin has a diverse mechanism of action, such as inhibition of cytochrome P450 (CYP) 2C9, protein binding replacement, lower absorption of vitamin K due to gut toxicity, and so forth. We experienced a case in which sunitinib, a molecular-targeted agent, was administered while undergoing warfarin, and the international normalized ratio of prothrombin time (PT-INR) increased remarkably. Here, we investigate the pharmacological mechanism of PT-INR increase in this patient both experimentally and in the literature. A 67-year-old man was stable with PT-INR (2.0-2.3) using warfarin for anticoagulation. A cancerous pleural effusion from renal cell carcinoma was observed, and sunitinib was started. Immediately after taking sunitinib, warfarin was reduced because PT-INR was elevated, but PT-INR increased further to 6.12 on Day 10 after sunitinib initiation. In in vitro experiments, sunitinib did not inhibit CYP2C9 at clinical concentrations. In this patient, sunitinib concentration was not changed under warfarin combination. Sunitinib shows a protein binding rate of < 95%, and since he had hypoalbuminemia, protein binding substitution may induce an increase in unbound warfarin. However, from the viewpoint of plasma concentrations of both drugs, protein binding substitution could not contribute to this interaction. It also suggests the contribution of insufficient intake and absorption of vitamin K owing to sunitinib-induced anorexia and gastrointestinal disturbances. Furthermore, the contribution of disseminated intravascular coagulation was indicated, as the D-dimer was high. Despite this case, careful monitoring of PT-INR is necessary when sunitinib and warfarin are combined, as the mechanism is not fully understood.
- 10 June 2017
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 43 (6) , 297-305
A Case Report of Elevated PT-INR Associated with Concurrent Use of Sunitinib and Warfarin:
Due to its interaction with many anticancer drugs, warfarin has a diverse mechanism of action, such as inhibition of cytochrome P450 (CYP) 2C9, protein binding replacement, lower absorption of vitamin K due to gut toxicity, and so forth. We experienced a case in which sunitinib, a molecular-targeted agent, was administered while undergoing warfarin, and the international normalized ratio of prothrombin time (PT-INR) increased remarkably. Here, we investigate the pharmacological mechanism of PT-INR increase in this patient both experimentally and in the literature. A 67-year-old man was stable with PT-INR (2.0-2.3) using warfarin for anticoagulation. A cancerous pleural effusion from renal cell carcinoma was observed, and sunitinib was started. Immediately after taking sunitinib, warfarin was reduced because PT-INR was elevated, but PT-INR increased further to 6.12 on Day 10 after sunitinib initiation. In in vitro experiments, sunitinib did not inhibit CYP2C9 at clinical concentrations. In this patient, sunitinib concentration was not changed under warfarin combination. Sunitinib shows a protein binding rate of < 95%, and since he had hypoalbuminemia, protein binding substitution may induce an increase in unbound warfarin. However, from the viewpoint of plasma concentrations of both drugs, protein binding substitution could not contribute to this interaction. It also suggests the contribution of insufficient intake and absorption of vitamin K owing to sunitinib-induced anorexia and gastrointestinal disturbances. Furthermore, the contribution of disseminated intravascular coagulation was indicated, as the D-dimer was high. Despite this case, careful monitoring of PT-INR is necessary when sunitinib and warfarin are combined, as the mechanism is not fully understood.
- Open Access
- 1 June 2017
- Published by Mammalogical Society of Japan in Mammal Study
- Vol. 42 (2) , 81-88
Intraspecific Variation in the Frequency of Multiple Paternity in the Japanese Wood Mouse (Apodemus speciosus)
The magnitude of intraspecific variation in the frequency of multiple paternity, and patterns in its relationship with other variables, was investigated in wild populations of the Japanese wood mouse Apodemus speciosus. The genotypes of 34 females and their offspring were determined on the basis of five microsatellite loci. A high proportion of litters (61.8% = 21/34 litters) were found to have been sired by multiple males. There was high variation in the proportion of multiple paternity in association with sampling localities and/or sampling years (27.3%–78.3%), which was higher than the interspecific variation shown by the proportion of multiple paternity across all studies (40.0%–65.2%) in the genus Apodemus (five species). This large magnitude of intraspecific variation might potentially affect the interpretation in previous studies making interspecific comparisons, and should therefore be taken into account as an important variable.
- 1 June 2017
- Published by Mammalogical Society of Japan in Mammal Study
- Vol. 42 (2) , 81-88
Open AccessIntraspecific Variation in the Frequency of Multiple Paternity in the Japanese Wood Mouse (Apodemus speciosus)
The magnitude of intraspecific variation in the frequency of multiple paternity, and patterns in its relationship with other variables, was investigated in wild populations of the Japanese wood mouse Apodemus speciosus. The genotypes of 34 females and their offspring were determined on the basis of five microsatellite loci. A high proportion of litters (61.8% = 21/34 litters) were found to have been sired by multiple males. There was high variation in the proportion of multiple paternity in association with sampling localities and/or sampling years (27.3%–78.3%), which was higher than the interspecific variation shown by the proportion of multiple paternity across all studies (40.0%–65.2%) in the genus Apodemus (five species). This large magnitude of intraspecific variation might potentially affect the interpretation in previous studies making interspecific comparisons, and should therefore be taken into account as an important variable.